Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 27:2021:4907167.
doi: 10.1155/2021/4907167. eCollection 2021.

The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials

Seidu A Richard  1 , Kuugbee D Eugene  2
Affiliations
Review

The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials

Seidu A Richard et al. Anal Cell Pathol (Amst). .

Abstract

Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase that encrypts a member of the Polycomb group (PcG) family. EZH2 forms a repressive chromatin structure which eventually participates in regulating the development as well as lineage propagation of stem cells and glioma progression. Posttranslational modifications are distinct approaches for the adjusted modification of EZH2 in the development of cancer. The amino acid succession of EZH2 protein makes it appropriate for covalent modifications, like phosphorylation, acetylation, O-GlcNAcylation, methylation, ubiquitination, and sumoylation. The glioma microenvironment is a dynamic component that comprises, besides glioma cells and glioma stem cells, a complex network that comprises diverse cell types like endothelial cells, astrocytes, and microglia as well as stromal components, soluble factors, and the extracellular membrane. EZH2 is well recognized as an essential modulator of cell invasion as well as metastasis in glioma. EZH2 oversecretion was implicated in the malfunction of several fundamental signaling pathways like Wnt/β-catenin signaling, Ras and NF-κB signaling, PI3K/AKT signaling, β-adrenergic receptor signaling, and bone morphogenetic protein as well as NOTCH signaling pathways. EZH2 was more secreted in glioblastoma multiforme than in low-grade gliomas as well as extremely secreted in U251 and U87 human glioma cells. Thus, the blockade of EZH2 expression in glioma could be of therapeutic value for patients with glioma. The suppression of EZH2 gene secretion was capable of reversing temozolomide resistance in patients with glioma. EZH2 is a promising therapeutic as well as prognostic biomarker for the treatment of glioma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
The posttranslational modifications of EZH2 and cascades.
Figure 2
Figure 2
Signaling pathways via which EZH2 modulates the glioma microenvironment.
See this image and copyright information in PMC

References

    1. Gladson C. L., Prayson R. A., Liu W. M. The pathobiology of glioma tumors. Annual Review of Pathological Mechanical Disease . 2010;5:33–50. - PMC - PubMed
    1. Seidu R. A., Wu M., Su Z., Xu H. Paradoxical role of high mobility group box 1 in glioma: a suppressor or a promoter? Oncology Reviews . 2017;11(1):p. 325. - PMC - PubMed
    1. Jiang M., Zhuang Y., Zu W. C., Jiao L., Richard S. A., Zhang S. Overexpression of EPAC2 reduces the invasion of glioma cells via MMP-2. Oncology letters . 2019;17(6):5080–5086. - PMC - PubMed
    1. Richard S. A. EPAC2: a new and promising protein for glioma pathogenesis and therapy. Oncology Reviews . 2020;14(1):p. 446. - PMC - PubMed
    1. Kleihues P., Louis D. N., Scheithauer B. W., et al. The WHO classification of tumors of the nervous system. Journal of Neuropathology & Experimental Neurology . 2002;61(3):215–225. doi: 10.1093/jnen/61.3.215. - DOI - PubMed

Substances